Novacta Biosystems Limited
About Novacta Biosystems
Novacta is a UK-based biotechnology company that specialises in the discovery and development of potential treatments for infectious diseases using a class of naturally occurring compounds called lantibiotics
Novacta's proprietary, patented technologies are in the fields of 'pathway engineering' (in which the pathways used by microorganisms are harnessed and exploited) and 'biotransformations' (in which natural catalysts called enzymes are used to perform otherwise complex chemistry in a cleaner and more efficient way than some traditional methods). These technologies are applied to manipulate the structure of natural lantibiotics and optimise them for use as therapeutic agents in areas of unmet medical need.
Novacta was established in 2003 and currently employs around 25 people; it recently moved to larger premises as part of BioPark Hertfordshire in Welwyn
- Focus : Manufacturer
- Industry : Pharma
Product portfolio of Novacta Biosystems
News about Novacta Biosystems
09-Aug-2012 | research and development
Novacta Biosystems Limited completes Phase I study of NVB302 against C. difficile infection in healthy volunteers
Celtic Pharma Holdings Advisors LLP announced that Novacta Biosystems Limited has completed a Phase I clinical trial of NVB302, the Company’s orally ...
18-Jun-2010 | business & finance
DSM to manufacture C. difficile compound for Novacta Biosystems
DSM BioSolutions announced that it has entered into an agreement with Novacta Biosystems Limited for the process development and cGMP production of its C. ...
14-Dec-2009 | business & finance
Novacta therapeutics and Oxygen Healthcare announce a multi FTE medicinal chemistry collaboration
Novacta Therapeutics and O2h announced a multi FTE chemistry collaboration to support their internal drug discovery efforts. This is the third successive ...
06-Apr-2009 | business & finance
Cambridge Major To Partner with Novacta Biosystems
Cambridge Major Laboratories and Novacta Biosystems have announced a collaboration combining respective expertise in process development, custom synthesis ...
26-Feb-2009 | people
Novacta Therapeutics Strengthens Leadership Team
Dr David Pompliano Appointed to the Board of Directors and as Chairman of the Scientific Advisory Board
17-Nov-2008 | research and development
Novacta Therapeutics and UK Ministry of Defence Announce Collaboration to Discover Novel Antiviral Therapeutics
Novacta Therapeutics announced that the UK's Defence Science and Technology Laboratory (DSTL) will evaluate its proprietary lantibiotics as a broad ...
16-Jan-2008 | business & finance
Novacta receives £3.5 million strategic translation award from the Wellcome trust ot target C. difficile infections
Novacta Biosystems, a UK-based anti-infective therapeutics company, announced that the Wellcome Trust, the UK's largest medical research charity, has ...